About VentureHealth
VentureHealth is a venture capital firm founded in 2012. It is primarily based out of San Jose, United States. As of Feb 2016, VentureHealth has invested in 64 companies. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to HealthTech and Enterprise Applications. Most recently it participated in the $***** Series D round of Rani Therapeutics Overall, VentureHealth portfolio has seen 5 IPOs and 3 acquisitions including key companies like Appian, Rani Therapeutics and HemoGenyx. A lot of funds co-invest with VentureHealth, with names like Google Ventures sharing a substantial percentage of its portfolio. VentureHealth has team of 2 people including 1 partners.Key Metrics
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
VentureHealth's List of Top Investments
VentureHealth has a portfolio of 64 companies. Their most notable investmentis in N Focus NeuroTheir portfolio spans across United States, Canada, United Kingdom and 8 more locations. They have invested in Life Sciences, HealthTech, Enterprise Applications and 14 other sectors, across stages such as Series B stage. Here is the list of top investments by VentureHealth:1. Appian
Cloud based low code application development and automation platform. The platform offers a solution that enables users to build applications without coding. The features of the product include business process management, document processing, case management, integration, automation, requirements management, risk governance, data fabrication, process mining, and more. It also provides automation technologies such as RPA, AI, IDP, and API integration. It provides its solutions to industries such as healthcare, insurance, life sciences, and more.
Key facts about Appian
- Founded Year: 1999
- Location: Reston (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $47.5M
- Employee Count: 2,033 as on Dec 31, 2024
- Investors: Saints Capital, Scheuermann Investment and 3 Others
- Latest Funding Round: Series B, Feb 28, 2014, $*****
- Highlight: Public
2. WHILL
Developer of wheelchairs for orthopedic support. It has developed personal electric vehicles with innovative design and state-of-the-art technology for personal mobility. It provides a device that is compact in size, has intuitive controls, wheels with Bluetooth controls, and 3G connectivity. The device can be connected to the mobile app remotely and users can access key device information and battery health to ensure the device is operating at its best. Using the device, users can charge their phones and provide voice notification alerts when it encounters operational errors. It has an anti-sway feature that helps keep the device driving in a straight line on side slopes. The device contains electromagnetic brakes that provide a safe stopping on inclines. It has also developed a device that contains a power sliding seat that allows users to pull right up to tables and desks and slide forward to a comfortable position.
Key facts about WHILL
- Founded Year: 2012
- Location: Shinagawa (Japan)
- Stage: Series D
- Total Funding till date: $125M
- Employee Count: 136 as on May 31, 2026
- Investors: SBI Investment, Locus Ventures and 22 Others
- Latest Funding Round: Series D, Jun 10, 2024, $*****
- Highlight: Editors' Pick
Developer of technology for the oral delivery of large drug molecules. The company has a proprietary platform is capable of delivering a wide range of biologics for the treatment of various chronic diseases. The company develops RaniPill capsule has broad applications for the treatment of acromegaly, rheumatoid arthritis, psoriatic arthritis, growth hormone deficiency, osteoporosis, Crohn’s disease, hemophilia, diabetes, among other diseases.
Key facts about Rani Therapeutics
- Founded Year: 2012
- Location: San Jose (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $226M
- Employee Count: 99 as on May 31, 2026
- Investors: Google Ventures, Alpha Square Group and 18 Others
- Latest Funding Round: Post IPO, Oct 23, 2025, $*****
- Highlight: Public
4. HemoGenyx
Developer of cell and gene therapies to treat blood diseases and viral infections. It offers apipeline of drug candidates which include HG‑CT‑1 CAR‑T therapy for relapsed or refractory acute myeloid leukemia, CDX Bi‑specific antibody to eliminate malignancy in patients with FLT3+ R/R AML and potentially condition bone marrow transplant, and Chimeric Bait Receptor Platform for antiviral and cancer immune cell reprogramming.
Key facts about HemoGenyx
- Founded Year: 2014
- Location: Buffalo (United States)
- Stage: Public
- Employee Count: 14 as on Dec 31, 2022
- Investors: Design Technologies, 43North and 3 Others
- Latest Funding Round: Post IPO, Feb 10, 2026, $*****
- Highlight: Public
5. Unyq
Personalized 3D-printed prosthetic covers empowering amputees to express their individuality. The company provides custom-designed prosthetic covers using cutting-edge 3D printing technology, blending functionality and style. These covers offer comfort, protection, and a way for users to express their unique style. They work closely with prosthetists and clinics, offering digital tools and innovative options. The company focuses on human-centered design, partnering with research and development entities and universities to create optimal solutions. They are committed to quality, ease, and individuality, aiming to make every step extraordinary. The company fosters a global community, redefining prosthetic care and enhancing lives through personalized solutions. They offer a range of designs, including custom, semi-custom, and joint covers, catering to various needs and preferences. The company is dedicated to innovation and improving the lives of amputees worldwide.
Key facts about Unyq
- Founded Year: 2014
- Location: San Francisco (United States)
- Annual Revenue: $1M - $10M as on Dec 31, 2019
- Stage: Series A
- Total Funding till date: $13.3M
- Employee Count: 29 as on May 31, 2026
- Investors: Graph Ventures, Farvatn Venture and 9 Others
- Latest Funding Round: Series A, Dec 14, 2018, $*****
- Highlight: Editors' Pick
VentureHealth's Investments by Stage
VentureHealth has made 2 investments in Series B stage with an average round size of $1.49M.VentureHealth's Investments by Sector
VentureHealth has a diverse portfolio, with companies operating in the Life Sciences and Enterprise Applications. Notably, it has invested in 53 Tech companies, 38 Enterprise (B2B) companies, 23 Software companies and at least 17 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 2 |
Enterprise Applications | 1 |
Note: We have considered here, only first round of investments
VentureHealth's Investments by Geography
VentureHealth has made most investments in United States (2).VentureHealth's recent investments
VentureHealth has not made any investment in 2026 so far.Here are the most recent investments by VentureHealth:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Feb 24, 2016 | United States | Series D | 6181 | [+7] | |
May 22, 2015 | United States | Series C | 8206 | [+3] | |
2014 | United States | Series B | 1288 | - | |
Aug 28, 2013 | United States | Series B | 5999 | [+1] |
IPOs and Publicly Listed companies in VentureHealth's Portfolio
5 of VentureHealth's portfolio companies have become public. Rani Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in Jul 2021 at marketcap of $528M and Appian got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $879M.Here are VentureHealth's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 30, 2021 | Aug 28, 2013 | Series B | 2725 | |
May 25, 2017 | - | - | 6577 | |
Nov 09, 2015 | - | - | 9225 | |
May 10, 2013 | - | - | 4748 | |
Sep 12, 1995 | - | - | 1419 |
Acquired companies in VentureHealth's Portfolio
3 companies from VentureHealth's portfolio have been acquired. The most recent acquisition was Sonoma Orthopedics in Jul 2017 by Arthrex for $*****.Here are VentureHealth's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 01, 2017 | - | - | 1856 | |
Apr 30, 2013 | - | - | 6148 | |
Feb 19, 2013 | 2014 | Series B | 5330 |
Team profile of VentureHealth
VentureHealth has a team of 2 members including 1 Partner and 1 Principal located in United States. VentureHealth's team does not sit on the board of any company as of now.Co-investors of VentureHealth
Over the past 13 years, 14 investors have co-invested in VentureHealth's portfolio companies. This includes funds and angels.
- Top Co-investors of VentureHealth: 2 investors entered a company along with VentureHealth. These include investors like Google Ventures (1 company).
- Invested after VentureHealth: A total of 12 investors have invested in VentureHealth's portfolio after their investments. Top Investors include GeneScience Pharmaceuticals (1 company), Shire (1 company) and Cathay Financial Holdings (1 company).
Recent News related to VentureHealth
•
Azitra Names Jeanne M. Bertonis as Chief Operating Officerpharmaceutical daily•Nov 19, 2019•Azitra, VentureHealth
•
•
•
Rani Therapeutics™ Secures Series C FundingPR Newswire•Rani Therapeutics, Novartis, InCube Ventures, VentureHealth and 2 others
•
